WARSAW, Ind., Nov. 12, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President & Chief Executive Officer is scheduled to participate in a fireside chat at two upcoming investor conferences being held in New York, NY.
| Event: | Stifel 2024 Healthcare Conference |
| Format: | Fireside Chat |
| Date: | Tuesday, November 19, 2024 |
| Time: | 10:55 am ET |
| Event: | Piper Sandler 36th Annual Healthcare Conference |
| Format: | Fireside Chat |
| Date: | Tuesday, December 3, 2024 |
| Time: | 9:00 am ET |
An audio webcast of the discussion will be available online at the OrthoPediatrics’ investor relations website, http://ir.orthopediatrics.com. Additionally, a replay will be available after the event.
About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 70 products that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit www.orthopediatrics.com.
Investor Contact
Philip Trip Taylor
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
415-937-5406
| Last Trade: | US$21.00 |
| Daily Change: | 0.41 1.99 |
| Daily Volume: | 101,768 |
| Market Cap: | US$508.620M |
January 13, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
